Vitrakvi
Tissue-Agnostic Trial Shows Frontline Vitrakvi Benefit in NTRK-Positive Pediatric Solid Tumors
In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.
In Brief This Week: Proteomics International, Children's Hospital of Philadelphia, Bayer
News items for the week of Nov. 20, 2023.